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The relative abilities of pneumococcal serotypes and strains (clones) to cause acute otitis media (AOM) were
investigated by comparing the serotypes and genotypes of pneumococci recovered from cases of AOM (n 149)
in children <2 years of age with those from nasopharyngeal carriage (n  288) in age-matched controls from
the same region. The odds ratio (OR) for association of pooled vaccine serotypes with AOM was found to be
slightly elevated over unity, although this was not significantly different from that of pooled nonvaccine or
vaccine-related serotypes. Comparing individual serotypes, 19F and 23F had 2- to 2.5-fold higher ORs,
although these were not markedly different from the ORs of nonvaccine serotypes. None of the major clones
had an OR that was significantly greater than the average, and the differences in ORs among serotypes and
clones were much less than those for invasive disease, suggesting little variation in their ability to cause AOM.
We conclude that serotype replacement may reduce the long-term efficacy of these vaccines against AOM.
Streptococcus pneumoniae (the pneumococcus) is one of the
major bacterial causes of acute otitis media (AOM) in chil-
dren, being responsible for between 30 and 50% of all cases (3,
13). The economic cost of AOM is high and is estimated to be
$5 billion per annum in the United States (4). One of the
contributing factors to this high cost is the high number of
antibiotic prescriptions for AOM, which is reflected in an in-
creasing prevalence of antibiotic resistance in pneumococci,
which in turn may complicate the treatment of AOM. Multi-
valent conjugate vaccines have recently been developed which
cover the pneumococcal serotypes most commonly associated
with invasive disease in developed countries. Clinical trials of
these vaccines have demonstrated 97% efficacy against invasive
pneumococcal disease caused by isolates of vaccine serotypes
(1). A separate study conducted in Finland found 57% efficacy
against AOM caused by pneumococci of vaccine serotypes (7).
Serotypes other than those covered by the vaccines cause a
significant proportion of AOM, and the overall reduction in
pneumococcal AOM in vaccinated children was 34%, with a
modest reduction in AOM due to all causes of about 6% (7).
An important finding of almost all trials of the conjugate
pneumococcal vaccines is not only a significant reduction in
nasopharyngeal (NP) carriage of pneumococci of vaccine se-
rotypes but also a concomitant increase in carriage of nonva-
ccine serotypes (12; S. K. Obaro, R. A. Adegbola, W. A. Banya,
and B. M. Greenwood, Letter, Lancet 348:271-272, 1996). The
mechanism, extent, duration, and consequences of this phe-
nomenon (serotype replacement) are subjects of current de-
bate (17; Obaro et al., letter).
S. pneumoniae is an antigenically diverse species in which
more than 90 serotypes have been identified. However, the
prevalence with which the serotypes are recovered from pa-
tients with invasive disease varies greatly (10), presumably be-
cause some serotypes have a much greater propensity to cause
invasive disease than others. If conjugate vaccines provide pro-
tection against those serotypes that are most invasive and re-
duce carriage and transmission of these serotypes, their imple-
mentation should lead to a sustained reduction in invasive
disease, as serotype replacement would increase exposure to
serotypes that are considered much less invasive than the vac-
cine serotypes. However, for mucosal infections like AOM, it is
much less clear whether there is a wide variation in the abilities
of different serotypes to cause disease. The association of the
common childhood serotypes (e.g., types 6B, 9V, 14, 19F, and
23F) with AOM is not necessarily evidence for any special
propensity of these to cause AOM, as these serotypes are the
ones most commonly carried in the nasopharynx of children (8,
19) and their association with AOM could merely reflect the
fact that they are the most likely to gain access to the middle
ear from the nasopharynx. Thus, even if all serotypes are
equally able to cause AOM, the majority of episodes of this
disease would be caused by the most frequently carried child-
hood serotypes.
It is important to know whether isolates of the vaccine se-
rotypes have a special ability to cause AOM, or whether almost
any pneumococcus that colonizes the nasopharynx has a sim-
ilar ability to cause AOM, as it impacts the long-term efficacy
of conjugate vaccines against this common childhood disease.
If isolates of vaccine serotypes cause most AOM because they
have a special ability to do so, compared to nonvaccine sero-
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types, there should be a sustained reduction in AOM even if
serotype replacement occurs. However, if isolates of nonvac-
cine serotypes were just as capable of causing AOM as those of
vaccine serotypes, serotype replacement following mass vacci-
nation would simply lead to AOM eventually being caused
predominantly by nonvaccine serotypes rather than by vaccine
serotypes, without substantially reducing the overall preva-
lence of disease.
We have asked whether pneumococcal serotypes, and indi-
vidual pneumococcal strains (clones), have an equal ability to
cause AOM, or whether some have a much greater propensity
to cause this disease, by comparing the frequency of serotypes
and clones of vaccine type (VT) and non-VT (NVT) pneumo-
cocci in the middle ear fluid (MEF) of children suffering from
AOM with the frequency of these serotypes and clones among
samples from NP carriage in the same group of Finnish chil-
dren. Our results show relatively small differences in the ability
of pneumococcal serotypes and clones to cause AOM, indicat-
ing that most serotypes, including nonvaccine serotypes, cause
AOM at a frequency that is proportional to their prevalence in
NP carriage. The implications for the long-term efficacy of
conjugate vaccines against AOM are discussed.
MATERIALS AND METHODS
Strains. Strains of S. pneumoniae were isolated from samples taken from
Finnish children as part of the FinOM Cohort Study between 1994 and 1997, in
which 329 unselected children from the Tampere region of Finland were mon-
itored from 2 to 24 months of age as part of a study of the natural history of
AOM. Ten NP swabs were obtained, with one being obtained at each of the
following ages: 2, 3, 4, 5, 6, 9, 12, 15, 18, and 24 months. Whenever symptoms of
acute infection suggesting AOM occurred, the parents were encouraged to bring
the child to the study clinic, in which one or two specially trained study physicians
diagnosed AOM by pneumatic otoscopy using fixed clinical criteria and tympa-
nometry as an aid (11). According to data collected at scheduled visits, 86% of
all cases of AOM occurring in these children during the follow-up were captured
at the study clinic. Whenever AOM with effusion occurred, a myringotomy was
performed and an MEF sample was aspirated for etiological diagnosis. Pneu-
mococci were cultured immediately from both NP and MEF samples on selective
plates and identified by standard methods in the bacteriology laboratory of the
National Public Health Institute in Oulu, Finland, as described in detail previ-
ously (11, 19). The strains were serotyped using antisera from the Statens Seru-
minstitut, Copenhagen, Denmark, and were stored as glycerol stocks at 80°C.
The strain from the MEF of each AOM event (n  201) was characterized by
multilocus sequence typing (MLST). Multiple strains from the same child were
included only if they were isolated at least 30 days apart or if they were different
strains (defined by MLST), in order to avoid repeated samples from the same
episode of AOM. Samples from AOM events in children 19.5 months old were
also excluded due to a lack of NP samples from the same age group for com-
parison (see below). With these definitions, there were 151 episodes of AOM in
the study cohort. For comparison with this data set, 297 S. pneumoniae controls
were randomly selected from the 397 NP isolates obtained from the 329 children
in the FinOM Cohort Study as described above, matched by age group (4.5, 4.5
to 7.5, 7.5 to 10.5, 10.5 to 13.5, 13.5 to 16.5, and 16.5 to 19.5 months). Two further
strains were removed from the MEF data set and nine strains were removed from
the NP data set on the grounds that sequence data obtained during MLST
showed them to be members of a species related to but distinct from true
pneumococci (see below). The final data included 149 isolates from episodes of
AOM and 288 control isolates from NP carriage.
MLST. Genomic DNA was isolated using DNeasy tissue kits (Qiagen Inc.,
Valencia, Calif.) and stored at 20°C. The allelic profile was determined by
amplifying internal fragments of the seven housekeeping loci used in the pneu-
mococcal MLST scheme (Taq polymerase and 10 buffer from Qiagen, 50 nM
concentrations of the deoxynucleoside triphosphates [Geneamp; Applied Bio-
systems, Foster City, Calif.], and the PCR conditions described previously [6]).
The PCR products were precipitated with 20% polyethylene glycol 8000–2.5 M
NaCl (Sigma) and the fragments were sequenced on both strands using the same
primers and BigDye II terminators (Applied Biosystems). The products of the
sequencing reactions were precipitated with 185 mM sodium acetate in 70%
ethanol and were resuspended in 10 l of HiDi Formamide (Applied Biosys-
tems) and loaded onto an ABI Prism 3700 sequencer. Sequences were analyzed
using STARS (obtainable from www.mlst.net), a modified Staden interface de-
veloped by Man-Suen Chan for use with MLST projects. Alleles at each locus
were assigned, and sequence types (STs) were determined, using the pneumo-
coccal MLST database (www.mlst.net).
Nontypeable presumptive pneumococcal isolates were separated into those
that were authentic pneumococci and those that were similar to, but genetically
distinct from, authentic pneumococci, by examination of the alleles at the seven
MLST loci (14). Authentic pneumococci had alleles at five or more loci that were
found in serotypeable pneumococci in the MLST database (or if novel were
similar to pneumococcal alleles), whereas those that were not authentic pneu-
mococci had alleles at two or more loci with97% identity with the most similar
pneumococcal allele in the MLST database.
Statistical analysis. Diversity of STs was assessed using Simpson’s index of
diversity D (16) as follows:
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where xi is the frequency of the ith ST, m is the number of STs, and N is the total
number of isolates; 95% confidence intervals (CI) were estimated by the method
of Grundmann et al. (9) as follows: CI  (D  2 	2, D  2 	2), where
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and where xj is the frequency of the jth ST and N is the total number of isolates
in the sample population.
Diversity of alleles at each locus was studied in an analogous way using the
above equations, where xi is the frequency of the ith allele and so on. This
measure for allelic diversity is equivalent to Nei’s h measure of heterozygosity
per locus (15) and was calculated for each MLST locus (h values). The mean
diversity over the seven MLST loci (H) was also calculated.
To adjust for potential confounding by age, controls were matched by age
group (see above). Separate analyses were performed for pooled vaccine, vac-
cine-related serotypes, and nonvaccine serotypes, as well as individual serotypes
and STs found at least 10 times in the combined sample of 149 cases (AOM) and
288 controls (NP); less-numerous types were pooled in a single class. For each
analysis (pooled VTs, serotypes, or STs), the distributions of types among cases
and controls were compared by determining the ratio of odds for exposure in
cases to that in controls. Specifically. to obtain a common reference for all
comparisons, the odds for any type were calculated as the geometric mean of
pairwise odds of the type with respect to all types in the analysis (this was realized
by using the deviation contrast in the SPSS software [18]). Without adjustment
for age, the odds ratio (OR) for type i may thus be calculated:

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where NjAOM and NjNP are the observed numbers of type j from cases (AOM)
and controls (NP), respectively, and m is the total number of types in the analysis
(10 for serotypes and 12 for STs). Logistic regression was used in the actual
analysis to adjust for age matching.
Although the two samples are not wholly independent (26 of 149 [17%] strains
from episodes of AOM were recovered during the same 3-month period as
strains from NP carriage from the same child), this did not markedly affect the
estimates of ORs reported here. ORs of 1 (or 1) indicate an increased (or
decreased) likelihood of a pneumococcal type being retrieved from patients with
AOM in comparison to the mean odds of AOM due to pneumococci of all types.
No corrections were made for multiple comparisons.
RESULTS
Comparison of vaccine and nonvaccine serotypes. The study
was designed to compare the distribution of serotypes and
individual clones (STs) of pneumococci causing AOM in chil-
dren with the distribution of those being carried by children of
the same age, in the same locality, during the same time pe-
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riod. All 437 isolates, 149 AOM case isolates and 288 NP
control isolates, were characterized by MLST and by serotyp-
ing. Nine serotypes were represented by at least 10 isolates in
the combined data set. Seven of these were vaccine serotypes
or vaccine-related serotypes, and two were nonvaccine sero-
types (11A and 35F). Comparison of the presence of VT and
NVT strains in cases and controls allows us to estimate the OR
for association of types with AOM. These are shown in Table
1. Pooled vaccine serotypes show an OR significantly greater
than unity, indicating an association with AOM, but when
compared with pneumococci of nonvaccine serotype, the 95%
CI overlap (although this is likely to be due to the sample size
in this study). The lack of a significant difference between
vaccine and nonvaccine serotypes suggests that the difference
in OR is small. Vaccine-related types were intermediate be-
tween vaccine and nonvaccine serotypes (Table 1).
Diversity of isolates from patients with AOM compared to
that of NP carriage isolates. If the isolates from patients with
AOM are a reflection of those that are being carried, the
diversities of the isolates in the AOM and NP data sets should
be similar. Diversity was assessed by calculating Simpson’s
index of diversity, D, for genotypes (STs) and individual MLST
loci (equivalent to Nei’s h). The 95% CI for D were estimated
(9), and for the diversity of STs in the NP data set (DNP 0.98

 0.002) and in the AOM data set (DAOM  0.98 
 0.003) the
CI overlapped, indicating that there was no significant differ-
ence in the genotypic diversities of these two populations. The
diversity at each of the seven individual MLST loci (h) and the
mean of these values (H) were also similar for the AOM and
NP data sets, and in all cases the CI overlapped (data not
shown).
While the overall genetic diversities of the two samples were
similar, their compositions in terms of the STs of the isolates
recovered from patients with AOM (cases) and carriage (con-
trols) could still be very different. Therefore, the distribution of
the STs of isolates from patients with AOM was compared to
that from carriage. Table 2 shows that all of the major STs
were represented in both the AOM and NP data sets. This was
also the case for most of the less abundant STs; none of the 26
STs that included at least five isolates were recovered only
from patients with AOM. Three of these 26 STs were recov-
TABLE 1. ORs for AOM of pooled vaccine and
nonvaccine serotypesa
Serotype
No. of isolates from: Total no.
of
isolates
OR (95% CI)
Carriage AOM
VT 156 97 253 1.35 (1.03–1.77)
R 55 24 79 0.95 (0.66–1.37)
NVT 77 28 105 0.78 (0.55–1.10)
a Numbers of isolates of VTs, vaccine-related (R) serotypes, and NVTs in the
AOM and carriage samples are shown with the associated ORs for AOM and the
95% CI, based on the logistic regression model. Total numbers of isolates
recovered from NP carriage and AOM were 288 and 149, respectively. ORs of
1 indicate a greater propensity to cause AOM; ORs of 1 signify a reduced
propensity to cause AOM. ORs significantly different from unity are shown in
boldface type.
TABLE 2. Properties and ORs of STs recovered from carriage and AOM isolatesa
ST
Allele no. at MLST loci
Serotype(s)
No. of isolates from: Total no.
of
isolates
OR (95% CI)b
aroE gdh gki recP spi xpt ddl Carriage AOM
62 2 5 29 12 16 3 14 11A 17 5 22 0.50 (0.19–1.32)
36 1 8 4 1 1 4 6 23F 14 6 20 0.73 (0.29–1.86)
37 1 8 6 2 6 4 6 23F 8 11 19 2.42 (0.99–5.90)
199 8 13 14 4 17 4 14 19A, 19F, 15 7, 2, 4 1, 3, 2 19 0.79 (0.31–2.02)
124 7 5 1 8 14 11 14 14 11 6 17 0.96 (0.37–2.50)
138 7 5 8 5 10 6 14 6B 14 3 17 0.36 (0.11–1.19)
485 1 5 1 1 1 1 8 19F 11 5 16 0.78 (0.28–2.17)
507 1 8 6 2 6 20 6 23F 9 4 13 0.78 (0.25–2.41)
309 8 10 2 5 9 48 6 19F 4 6 10 2.61 (0.78–8.78)
460 5 7 4 10 10 1 27 6A 6 4 10 1.15 (0.34–3.83)
488 2 13 9 1 6 28 14 6A 4 6 10 2.70 (0.81–8.99)
66 2 8 2 4 6 1 1 9N, 23F, 19F 5, 0, 0 1, 1, 2 9
162 7 11 10 1 6 8 14 9V 5 4 9
504 1 8 1 2 6 56 6 23F 4 5 9
423 1 5 4 12 5 3 8 19F 5 3 8
205 10 5 4 5 13 10 18 4 6 2 8
481 5 1 4 2 10 1 27 6A 7 0 7
15 1 5 4 5 5 3 8 15 4 3 7
497 7 25 4 2 48 20 28 6B 3 3 6
520 1 1 4 1 18 16 17 22, R 4, 0 0, 2 6
490 2 13 9 1 6 19 14 6A, 6B 3, 2 0, 1 6
176 7 13 8 6 10 6 14 6B 4 1 5
492 7 5 1 1 6 31 9 6B 4 1 5
191 8 9 2 1 6 1 17 7F 4 1 5
487 2 1 1 1 10 1 14 35F 5 0 5
273 5 6 2 2 6 1 14 6B 5 0 5
Other 107 57 164
Total 288 149 437
a STs recovered five or more times from the combined carriage and AOM data sets are shown together with their-allelic profiles and serotypes.
b ORs and 95% CI based on the logistic regression model are shown for STs recovered 10 times from the combined data set.
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ered exclusively from carriage isolates; two were vaccine or
vaccine-related serotypes (ST 481, serotype 6A, seven isolates;
ST 273, serotype 6B, five isolates), and the other was an NVT
(ST 487, serotype 35F, five isolates). Thus, only 3 of the 26
most-abundant STs were found in only one of the data sets.
There was no significant difference in distribution of AOM
and NP isolates within the 11 STs represented by at least 10
isolates (Fisher’s exact test; P  0.18). The isolates from pa-
tients with AOM and the carriage isolates were therefore not
significantly different in their overall diversity or in their geno-
types.
Serotypes and clones present in the NP and AOM data sets.
The major STs and serotypes identified by MLST in the NP
and AOM data sets are shown in Tables 2 and 3, respectively.
Full versions of these tables are available from the authors on
request. The combined data set contained 104 different STs.
There were 11 STs that included 10 or more isolates and 31
STs for which only a single isolate was sampled. In the majority
of cases, all isolates with the same ST had the same serotype.
However, there were some exceptions, where isolates of dif-
fering serotypes were found within a single ST (STs 66, 199,
490, and 520). In addition to those strains shown in Table 2,
three isolates of ST 71 that expressed the 15A capsule were
found, and one expressed the 11A capsule. Only one of these,
a 15A isolate, was recovered from MEF. All potential cases of
serotype switching were confirmed by both reserotyping and
resequencing the MLST loci.
Association of serotypes and clones with AOM and carriage.
While the ORs reported above indicate a slightly elevated
association of AOM with carriage of VT pneumococci, this
does not exclude the possibility that an individual serotype(s)
could be strongly associated with either AOM or carriage but
that this is obscured when numerous different capsular types
(which may have quite different immunological properties) are
pooled.
To investigate any possible differences in the propensity of
individual serotypes or STs to cause disease, ORs were esti-
mated for the most common serotypes and STs (Tables 2 and
3). Serotypes 19F and 23F (Table 3) showed significantly ele-
vated ORs. The lowest OR was associated with serotype 35F.
For the individual clones (STs), ORs were calculated for those
STs present 10 times or more in the combined data set. Even
for these clones, wide CI make it hard to draw definitive con-
clusions. However, the serotype 23F clone, ST 37, may be
associated with AOM, and STs 309 and 488, which are, respec-
tively, 19F and 6A clones, may be also, although in both these
cases our interpretation must be limited by the small numbers
sampled which limit statistical power. In contrast, the 6B clone,
ST 138, may be associated with carriage. Note, however, that
95% confidence limits for the ORs of all STs studied included
1, and while this may be a consequence of sample size, it
suggests that any differences in ability to cause AOM are slight.
DISCUSSION
In this work we have compared the abilities of vaccine and
nonvaccine serotypes, as well as individual serotypes and
clones (STs), to cause AOM by comparing the pneumococci
causing AOM in young children with those that are carried by
children of the same age, in the same region, during the same
time period. This approach provides much more meaningful
information than assessing the disease potential of serotypes
by looking at their rank prevalence in causing disease, as the
latter approach fails to take into account any differences in
exposure to each serotype. Thus, a serotype that has a high
disease potential will cause little disease if exposure to it is
rare, and conversely, serotypes with relatively low disease po-
tential may be the most frequently recovered from disease if
exposure to them is very common (5).
We wished to assess whether there were serotypes or clones
of S. pneumoniae with a special propensity to cause AOM or
whether different serotypes and clones had an approximately
equal ability to cause AOM, to enable us to assess the likely
long-term impact of conjugate vaccines on AOM due to S.
pneumoniae. Pneumococcal serotypes in most cases include a
number of genetically diverse clones (6), and precise molecular
characterization of the strains from disease and carriage can be
used to look at the ability of individual clones to cause disease
and can address any variation in disease potential within a
serotype. Furthermore, where a clone includes isolates of two
TABLE 3. ORs for AOM of major pneumococcal serotypesa
Serotype
Isolates (n)
Total OR (95% CI) No. ofSTs Most common STs (n)Carriage AOM
19Fb 38 34 72 2.46 (1.43–4.21) 16 485 (16), 309 (9)
23Fb 41 29 70 1.96 (1.13–3.40) 8 36 (20), 37 (19)
6Bb 48 12 60 0.67 (0.35–1.30) 16 138 (17), 497 (6)
6A 35 19 54 1.51 (0.82–2.78) 17 460 (10), 488 (10)
11A 24 8 32 0.89 (0.40–1.98) 6 62 (22)
14b 14 11 25 2.18 (0.99–4.81) 4 124 (17)
35F 15 1 16 0.18 (0.03–1.13) 4 487 (5)
19A 9 2 11 0.60 (0.15–2.48) 2 199 (8)
9N 8 2 10 0.67 (0.16–2.79) 3 66 (6)
Other 56 31 87 1.47 (0.88–2.48) 31 162 (9)
Total 288 149 437
a Numbers of isolates of the most prevalent serotypes in the AOM and carriage isolates are shown with the associated ORs for progression to AOM and the 95%
CI, based on the logistic regression model. Only serotypes recovered at least 10 times are shown. “Other” refers to the isolates of all other serotypes. ORs significantly
different from unity are shown in boldface type.
b Serotype present in the licensed 7-valent conjugate vaccine.
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different serotypes, any difference in disease potential can be
assessed and, as the isolates are indistinguishable by MLST,
can be postulated to be due to the difference in capsular type
(although the possibility of variation at other, unsequenced
virulence genes cannot be excluded).
There were several indications from this study that there are
relatively small differences in the ability of different serotypes
or clones to cause AOM. While pooled VTs were found to be
more likely to cause AOM, the difference was small, and in-
deed the CI for the ORs of VTs and NVTs were found to
overlap, although this is likely to be a consequence of the small
sample size. Differences in the abilities of individual serotypes
to cause AOM were suggested by comparison of their ORs (for
example, serotypes 14 and 35F), but again the differences were
small, and only serotypes 19F and 23F showed a small but
significant association with AOM (Table 3). Because relatively
few isolates of nonvaccine serotypes were found in this study,
it is hard to directly compare the type-specific ORs of these
with those of individual vaccine serotypes. However, the OR of
serotype 11A, a common cause of AOM among Finnish chil-
dren, was similar to that of many of the vaccine serotypes,
demonstrating that nonvaccine serotypes may not be less able
to cause AOM than those included within the 7-valent conju-
gate vaccine.
This study has revealed considerable diversity in both sero-
types and clones within those pneumococci retrieved from
cases of AOM and NP carriage. As a consequence, many
serotypes and STs were not present in sufficient numbers to
furnish statistical power to detect an association with carriage
or AOM, and it is likely that a larger sample size would have
detected significant differences between the ORs of these.
However, we would not expect it to uncover major clones
strongly associated with either of these states, but rather to
improve our estimates of the small differences we may infer. In
contrast, large differences were found in a recent study of
invasive pneumococcal disease in the Oxford region, which
used a sample size similar to that in this study. A large range of
ORs was found for both serotypes (between 0.1 and 12.1) and
individual STs (between 0.1 and 8.3). In the present study, ORs
for serotypes ranged between 0.18 and 2.46 and for STs be-
tween 0.36 and 2.7 (Tables 2 and 3). This suggests that the
sample size here should be able to detect large differences, if
they exist, and the failure to find such differences indicates that
there is less variation in the ability of STs and serotypes to
cause AOM than to cause invasive disease.
Similarly, isolates from invasive disease were significantly
less diverse than those from carriage, and there was a highly
nonrandom distribution of isolates of the major clones among
the samples from carriage and invasive disease. In contrast, no
differences were found in our study, suggesting that the isolates
that cause AOM are not clearly different from those that are
carried in the nasopharynx. There was no evidence of major
clones which are carried but do not cause AOM.
Serotypes 19F and 23F appeared to be slightly more able to
cause AOM than isolates of the other serotypes that were
prevalent in our data set (Table 3). There is some evidence that
possession of the serotype 19F capsule may predispose slightly
towards the development of AOM. ST 66 included isolates of
serotypes 23F, 19F, and 9N, indicating a history of serotype
switching within this clone. If we consider the distribution of
serotypes between carriage and AOM isolates in this serotypi-
cally mixed clone (Table 2), all but one of the six isolates of
serotype 9N are from carriage, whereas all of the serotype 19F
and 23F isolates are from patients with AOM. This suggests
that serotype 19F and 23F isolates may be more commonly
recovered from patients with AOM than isolates with the same
genotype that express the serotype 9N capsule. Any greater
propensity of serotype 19F to cause AOM is unfortunate, as in
clinical trials the present formulations of the conjugate vac-
cines were least effective against this serotype (point estimate
for efficacy against AOM due to serotype 19F  25%) (7).
There is some evidence for a difference in the ability of
clones of the same serotype to cause AOM, which would sug-
gest a contribution of genotype as well as capsular type to the
ability to cause AOM. STs 37, 36, and 507 all express 23F
capsules, but the ORs for these STs may be different (Table 2),
although a larger sample is needed to confirm this. For invasive
disease, there were no apparent differences among clones of
the same serotype, and serotype may be an important, and
perhaps the predominant, marker of invasive disease potential
(5). In mucosal infections, such as AOM, the situation appears
to be different, and serotype may play a lesser role in deter-
mining the ability of a strain to cause disease. A difference in
the importance of capsular serotype is supported by the fact
that nontypeable or unencapsulated pneumococci are very
rarely associated with invasive disease, whereas these strains
are relatively frequently recovered from patients with AOM
(four unencapsulated pneumococci were recovered in this
study).
If the capsule plays a less important role in disease, serotype
replacement may be expected to reduce the effectiveness of the
conjugate vaccines against AOM. Some support for this pos-
sibility comes from the Finnish trial, in which an increase in
carriage of nonvaccine serotypes was mirrored by a significant
increase in AOM due to these serotypes (7). However, over the
course of the trial this was not sufficient to eliminate the re-
duction in AOM, and comparison of tympanostomy tube
placements in vaccinated and unvaccinated children from 2 to
4 or 5 years of age showed a significant reduction in the vac-
cinated children (A. Palmu, J. Verho, P. H. Makela, and T.
Kilpi, Abstr. 3rd Int. Symp. Pneumococci Pneumococcal Dis.,
2002, p. 72). Also note that a completely vaccinated population
would be expected to result in greater selective pressure in
favor of nonvaccine serotypes than has been the case in any of
the trials reported to date, in which the vaccinated population
mixed freely with the nonvaccinated majority. This may result
in a more extensive replacement phenomenon than we have
seen in the efficacy studies.
The efficacy of conjugate vaccines against pneumonia has
not been thoroughly assessed, and much less is known about
the strains and serotypes from pneumonia than about those
from invasive disease. Protection against bacteremic pneumo-
nia caused by vaccine serotypes appears to be as effective as
that against invasive disease, which is consistent with protec-
tion against bacteremia (2). However, nonbacteremic pneumo-
nia may more closely resemble a mucosal infection than an
invasive infection. Nonbacteremic pneumonia is one of the
most significant contributors to the morbidity and mortality of
pneumococcal disease (although less serious than meningitis
or bacteremic pneumonia, it is far more common). It will be
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important to assess whether nonbacteremic pneumonia is
more similar to invasive disease or a mucosal infection such as
AOM, where there appears to be much less variation in the
ability of serotypes and clones to cause disease. If the latter is
true, we might expect serotype replacement to reduce the
effectiveness of conjugate vaccines against this form of pneu-
monia, since the replacing nonvaccine serotypes may have con-
siderable pathogenic potential.
In conclusion, we have demonstrated that there appear to be
smaller differences in the abilities of different pneumococcal
serotypes and clones to cause AOM than is found with invasive
disease, and following serotype replacement, this has the po-
tential to reduce the efficacy of the conjugate vaccines against
AOM. Surveillance for changes in the serotypes causing AOM,
and for loss of vaccine efficacy, is required following mass
vaccination, but tympanocentesis is now rarely undertaken,
and the numbers of isolates obtained from patients with AOM
may not be sufficient to observe any changes that occur.
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